Literature DB >> 34135024

Advancing American Kidney Health and the Role of Sodium-Glucose Cotransporter-2 Inhibitors: A Missed Opportunity.

Jiahua Li1, Sri Lekha Tummalapalli2, Mallika L Mendu3,4.   

Abstract

Entities:  

Keywords:  SGLT2i; United States; chronic kidney disease; diabetes mellitus; proteinuria; sodium-glucose transporter 2; sodium-glucose transporter 2 inhibitors; type 2

Mesh：

Substances：

Year:  2021        PMID： 34135024      PMCID： PMC8499015          DOI： 10.2215/CJN.05450421

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  7 in total

1.  Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

Authors:  Meg J Jardine; Zien Zhou; Kenneth W Mahaffey; Megumi Oshima; Rajiv Agarwal; George Bakris; Harpreet S Bajaj; Scott Bull; Christopher P Cannon; David M Charytan; Dick de Zeeuw; Gian Luca Di Tanna; Tom Greene; Hiddo J L Heerspink; Adeera Levin; Bruce Neal; Carol Pollock; Rose Qiu; Tao Sun; David C Wheeler; Hong Zhang; Bernard Zinman; Norman Rosenthal; Vlado Perkovic
Journal:  J Am Soc Nephrol       Date:  2020-05       Impact factor: 10.121

2.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.

Authors:  Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El Nahas; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Bertram L Kasiske; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2010-12-08       Impact factor: 10.612

3.  KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int       Date:  2020-10       Impact factor: 10.612

4.  Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control.

Authors:  Benjamin M Scirica; Christopher P Cannon; Naomi D L Fisher; Thomas A Gaziano; David Zelle; Kira Chaney; Angela Miller; Hunter Nichols; Lina Matta; William J Gordon; Shawn Murphy; Kavi B Wagholikar; Jorge Plutzky; Calum A MacRae
Journal:  Circulation       Date:  2020-11-17       Impact factor: 29.690

5.  Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.

Authors:  Rozalina G McCoy; Holly K Van Houten; Yihong Deng; Pinar Karaca Mandic; Joseph S Ross; Victor M Montori; Nilay D Shah
Journal:  JAMA Netw Open       Date:  2021-02-01

6.  Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.

Authors:  Michael Willis; Andreas Nilsson; Klas Kellerborg; Philip Ball; Rupert Roe; Shana Traina; Rebecca Beale; Isabelle Newell
Journal:  Diabetes Ther       Date:  2020-12-02       Impact factor: 2.945

7.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Authors:  Jing Luo; Robert Feldman; Scott D Rothenberger; Inmaculada Hernandez; Walid F Gellad
Journal:  JAMA Netw Open       Date:  2020-10-01
  7 in total
  2 in total

1.  Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.

Authors:  Min Zhuo; Jiahua Li; Leo F Buckley; Sri Lekha Tummalapalli; David B Mount; David J R Steele; David J Lucier; Mallika L Mendu
Journal:  Kidney360       Date:  2022-01-19

Review 2.  Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD.

Authors:  Alexander J Kula
Journal:  Pediatr Nephrol       Date:  2022-01-27       Impact factor: 3.651
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.